Scott Drutman Incoming Chief Medical Officer of Enara Bio Boehringer Ingelheim exercises option to license additional Dark ...

MISSISSAUGA, ON / ACCESS Newswire / January 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial usage ...

Researchers from Children's Hospital of Philadelphia (CHOP) have developed a method to help cancer immunotherapies reach ...

GSK will be filing for approval of bepirovirsen in hepatitis B to global regulatory authorities based on the Phase III data.

Cell-based immunotherapies have transformed cancer treatment, yet their widespread use remains constrained by safety risks, ...

Topline data were announced from two phase 3 studies evaluating bepirovirsen for the treatment of chronic hepatitis B.

A new study published in Nature Communications provides a framework for researching whether earlier, model-guided treatment ...

Conventional vaccine adjuvants primarily rely on molecular binding and biochemical stimulation to activate immune responses, ...

MISSISSAUGA, ON / ACCESS Newswire / January 7, 2026 / Microbix Biosystems Inc. (TSX:MBX)(OTCQX:MBXBF) (Microbix), a life sciences innovator, manufacturer, and exporter, announces the commercial usage ...

Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study ...

Detailed price information for Microbix Biosystems Inc (MBXBF) from The Globe and Mail including charting and trades.

SHENZHEN -- Chinese researchers have developed an innovative "intratumoral vaccine" molecule that prevents cancer cells from ...